These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

110 related items for PubMed ID: 21040217

  • 1. BPR0C261 is a novel orally active antitumor agent with antimitotic and anti-angiogenic activities.
    Hu CB, Chen CP, Yeh TK, Song JS, Chang CY, Chuu JJ, Tung FF, Ho PY, Chen TW, Lin CH, Wang MH, Chang KY, Huang CL, Lin HL, Li WT, Hwang DR, Chern JH, Hwang LL, Chang JY, Chao YS, Chen CT.
    Cancer Sci; 2011 Jan; 102(1):182-91. PubMed ID: 21040217
    [Abstract] [Full Text] [Related]

  • 2. Antiangiogenic activities and cisplatin-combined antitumor activities of BPR0L075.
    Chen CP, Hu CB, Yeh KC, Song JS, Yeh TK, Tung FF, Hwang LL, Tseng HY, Huang YC, Shy HS, Hsieh SH, Shen CC, Wang HS, Hsieh HP, Liou JP, Chao YS, Chen CT.
    Anticancer Res; 2010 Jul; 30(7):2813-22. PubMed ID: 20683017
    [Abstract] [Full Text] [Related]

  • 3. CEP-7055: a novel, orally active pan inhibitor of vascular endothelial growth factor receptor tyrosine kinases with potent antiangiogenic activity and antitumor efficacy in preclinical models.
    Ruggeri B, Singh J, Gingrich D, Angeles T, Albom M, Yang S, Chang H, Robinson C, Hunter K, Dobrzanski P, Jones-Bolin S, Pritchard S, Aimone L, Klein-Szanto A, Herbert JM, Bono F, Schaeffer P, Casellas P, Bourie B, Pili R, Isaacs J, Ator M, Hudkins R, Vaught J, Mallamo J, Dionne C.
    Cancer Res; 2003 Sep 15; 63(18):5978-91. PubMed ID: 14522925
    [Abstract] [Full Text] [Related]

  • 4. BPR0L075, a novel synthetic indole compound with antimitotic activity in human cancer cells, exerts effective antitumoral activity in vivo.
    Kuo CC, Hsieh HP, Pan WY, Chen CP, Liou JP, Lee SJ, Chang YL, Chen LT, Chen CT, Chang JY.
    Cancer Res; 2004 Jul 01; 64(13):4621-8. PubMed ID: 15231674
    [Abstract] [Full Text] [Related]

  • 5. Antitumor activity of orally bioavailable farnesyltransferase inhibitor, ABT-100, is mediated by antiproliferative, proapoptotic, and antiangiogenic effects in xenograft models.
    Ferguson D, Rodriguez LE, Palma JP, Refici M, Jarvis K, O'Connor J, Sullivan GM, Frost D, Marsh K, Bauch J, Zhang H, Lin NH, Rosenberg S, Sham HL, Joseph IB.
    Clin Cancer Res; 2005 Apr 15; 11(8):3045-54. PubMed ID: 15837760
    [Abstract] [Full Text] [Related]

  • 6. BPR0C305, an orally active microtubule-disrupting anticancer agent.
    Li WT, Yeh TK, Song JS, Yang YN, Chen TW, Lin CH, Chen CP, Shen CC, Hsieh CC, Lin HL, Chao YS, Chen CT.
    Anticancer Drugs; 2013 Nov 15; 24(10):1047-57. PubMed ID: 24025560
    [Abstract] [Full Text] [Related]

  • 7. Synthesis and biological activities of 2-amino-1-arylidenamino imidazoles as orally active anticancer agents.
    Li WT, Hwang DR, Song JS, Chen CP, Chuu JJ, Hu CB, Lin HL, Huang CL, Huang CY, Tseng HY, Lin CC, Chen TW, Lin CH, Wang HS, Shen CC, Chang CM, Chao YS, Chen CT.
    J Med Chem; 2010 Mar 25; 53(6):2409-17. PubMed ID: 20170097
    [Abstract] [Full Text] [Related]

  • 8. Synthesis and biological evaluation of N-heterocyclic indolyl glyoxylamides as orally active anticancer agents.
    Li WT, Hwang DR, Chen CP, Shen CW, Huang CL, Chen TW, Lin CH, Chang YL, Chang YY, Lo YK, Tseng HY, Lin CC, Song JS, Chen HC, Chen SJ, Wu SH, Chen CT.
    J Med Chem; 2003 Apr 24; 46(9):1706-15. PubMed ID: 12699388
    [Abstract] [Full Text] [Related]

  • 9. Synthesis and biological evaluation of diarylthiazole derivatives as antimitotic and antivascular agents with potent antitumor activity.
    Wang F, Yang Z, Liu Y, Ma L, Wu Y, He L, Shao M, Yu K, Wu W, Pu Y, Nie C, Chen L.
    Bioorg Med Chem; 2015 Jul 01; 23(13):3337-50. PubMed ID: 25937236
    [Abstract] [Full Text] [Related]

  • 10. Tricyclic pyrone analogs: a new synthetic class of bifunctional anticancer drugs that inhibit nucleoside transport, microtubule assembly, the viability of leukemic cells in vitro and the growth of solid tumors in vivo.
    Perchellet EM, Ladesich JB, Magill MJ, Chen Y, Hua DH, Perchellet JP.
    Anticancer Drugs; 1999 Jun 01; 10(5):489-504. PubMed ID: 10477169
    [Abstract] [Full Text] [Related]

  • 11. Chemosensitization and radiosensitization of human lung and colon cancers by antimitotic agent, ABT-751, in athymic murine xenograft models of subcutaneous tumor growth.
    Jorgensen TJ, Tian H, Joseph IB, Menon K, Frost D.
    Cancer Chemother Pharmacol; 2007 May 01; 59(6):725-32. PubMed ID: 16967299
    [Abstract] [Full Text] [Related]

  • 12. Double blockade of cell cycle at g(1)-s transition and m phase by 3-iodoacetamido benzoyl ethyl ester, a new type of tubulin ligand.
    Jiang JD, Denner L, Ling YH, Li JN, Davis A, Wang Y, Li Y, Roboz J, Wang LG, Perez-Soler R, Marcelli M, Bekesi G, Holland JF.
    Cancer Res; 2002 Nov 01; 62(21):6080-8. PubMed ID: 12414632
    [Abstract] [Full Text] [Related]

  • 13. Hypoestoxide, a natural nonmutagenic diterpenoid with antiangiogenic and antitumor activity: possible mechanisms of action.
    Ojo-Amaize EA, Nchekwube EJ, Cottam HB, Bai R, Verdier-Pinard P, Kakkanaiah VN, Varner JA, Leoni L, Okogun JI, Adesomoju AA, Oyemade OA, Hamel E.
    Cancer Res; 2002 Jul 15; 62(14):4007-14. PubMed ID: 12124334
    [Abstract] [Full Text] [Related]

  • 14. 7-Diethylamino-3(2'-benzoxazolyl)-coumarin is a novel microtubule inhibitor with antimitotic activity in multidrug resistant cancer cells.
    Kim SN, Kim NH, Park YS, Kim H, Lee S, Wang Q, Kim YK.
    Biochem Pharmacol; 2009 Jun 15; 77(12):1773-9. PubMed ID: 19428332
    [Abstract] [Full Text] [Related]

  • 15. AEE788: a dual family epidermal growth factor receptor/ErbB2 and vascular endothelial growth factor receptor tyrosine kinase inhibitor with antitumor and antiangiogenic activity.
    Traxler P, Allegrini PR, Brandt R, Brueggen J, Cozens R, Fabbro D, Grosios K, Lane HA, McSheehy P, Mestan J, Meyer T, Tang C, Wartmann M, Wood J, Caravatti G.
    Cancer Res; 2004 Jul 15; 64(14):4931-41. PubMed ID: 15256466
    [Abstract] [Full Text] [Related]

  • 16. Voreloxin, formerly SNS-595, has potent activity against a broad panel of cancer cell lines and in vivo tumor models.
    Hoch U, Lynch J, Sato Y, Kashimoto S, Kajikawa F, Furutani Y, Silverman JA.
    Cancer Chemother Pharmacol; 2009 Jun 15; 64(1):53-65. PubMed ID: 18931998
    [Abstract] [Full Text] [Related]

  • 17. Mechanism of action of E7010, an orally active sulfonamide antitumor agent: inhibition of mitosis by binding to the colchicine site of tubulin.
    Yoshimatsu K, Yamaguchi A, Yoshino H, Koyanagi N, Kitoh K.
    Cancer Res; 1997 Aug 01; 57(15):3208-13. PubMed ID: 9242451
    [Abstract] [Full Text] [Related]

  • 18. Salvinal, a novel microtubule inhibitor isolated from Salvia miltiorrhizae Bunge (Danshen), with antimitotic activity in multidrug-sensitive and -resistant human tumor cells.
    Chang JY, Chang CY, Kuo CC, Chen LT, Wein YS, Kuo YH.
    Mol Pharmacol; 2004 Jan 01; 65(1):77-84. PubMed ID: 14722239
    [Abstract] [Full Text] [Related]

  • 19. Pseudolaric acid B, a novel microtubule-destabilizing agent that circumvents multidrug resistance phenotype and exhibits antitumor activity in vivo.
    Wong VK, Chiu P, Chung SS, Chow LM, Zhao YZ, Yang BB, Ko BC.
    Clin Cancer Res; 2005 Aug 15; 11(16):6002-11. PubMed ID: 16115945
    [Abstract] [Full Text] [Related]

  • 20. Discovery of novel 2-N-aryl-substituted benzenesulfonamidoacetamides: orally bioavailable tubulin polymerization inhibitors with marked antitumor activities.
    Liu Z, Zhou Z, Tian W, Fan X, Xue D, Yu L, Yu Q, Long YQ.
    ChemMedChem; 2012 Apr 15; 7(4):680-93. PubMed ID: 22311585
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 6.